Patents Assigned to Tetralogic Pharmaceuticals Corporation
-
Publication number: 20150307448Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.Type: ApplicationFiled: July 16, 2014Publication date: October 29, 2015Applicant: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
-
Publication number: 20150190470Abstract: A combination therapy comprising administration of a Smac mimetic and GM-CSF.Type: ApplicationFiled: August 1, 2013Publication date: July 9, 2015Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: C. Glenn Begley, Christopher Benetatos, Srinivas Chunduru
-
Patent number: 8986993Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.Type: GrantFiled: November 8, 2013Date of Patent: March 24, 2015Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Yijun Deng, Matthew G. LaPorte, Susan R. Rippin
-
Publication number: 20140329823Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.Type: ApplicationFiled: July 21, 2014Publication date: November 6, 2014Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Matthew G. Laporte, Yijun DENG, Susan R. Rippin
-
Publication number: 20140303090Abstract: A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.Type: ApplicationFiled: April 7, 2014Publication date: October 9, 2014Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Srinivas K. Chunduru, Yasuhiro Mitsuuchi, James Vince, John Silke
-
Patent number: 8822525Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.Type: GrantFiled: June 25, 2013Date of Patent: September 2, 2014Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20140243276Abstract: A method of using a Smac mimetic and pharmaceutical compositions thereof.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: David Weng, Srinivas Chunduru, Martin Graham
-
Patent number: 8802716Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPB (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.Type: GrantFiled: June 25, 2013Date of Patent: August 12, 2014Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Patent number: 8497297Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.Type: GrantFiled: August 2, 2011Date of Patent: July 30, 2013Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippen
-
Patent number: 8481495Abstract: The present invention describes compounds of the formula pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.Type: GrantFiled: May 25, 2010Date of Patent: July 9, 2013Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Yijun Deng, Matthew D. Alexander, Matthew G. Laporte
-
Publication number: 20130040893Abstract: Inhibitors of cIAP-1 and methods and compositions for treating proliferative disorders.Type: ApplicationFiled: April 13, 2012Publication date: February 14, 2013Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stacy SPRINGS, Mark McKINLAY, Sri CHUNDURU, Chris BENETATOS
-
Publication number: 20120184530Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.Type: ApplicationFiled: March 27, 2012Publication date: July 19, 2012Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventor: Stephen M. CONDON
-
Publication number: 20120157390Abstract: Smac mimetics that inhibit IAPs.Type: ApplicationFiled: February 29, 2012Publication date: June 21, 2012Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. CONDON, Matthew G. LaPORTE, Yijun DENG, Susan R. RIPPIN
-
Patent number: 8143426Abstract: Smac mimetics that inhibit IAPs.Type: GrantFiled: July 24, 2007Date of Patent: March 27, 2012Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20110305777Abstract: Smac mimetics that inhibit IAPs.Type: ApplicationFiled: June 9, 2011Publication date: December 15, 2011Applicant: Tetralogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20110294827Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.Type: ApplicationFiled: June 3, 2011Publication date: December 1, 2011Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Patent number: 8022230Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.Type: GrantFiled: March 13, 2009Date of Patent: September 20, 2011Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Patent number: 7985735Abstract: Smac mimetics that inhibit IAPs.Type: GrantFiled: July 24, 2007Date of Patent: July 26, 2011Assignee: Tetralogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Patent number: 7968590Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.Type: GrantFiled: October 9, 2008Date of Patent: June 28, 2011Assignee: Tetralogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20110003877Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.Type: ApplicationFiled: June 20, 2010Publication date: January 6, 2011Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Yijun Deng, Matthew G. LaPorte, Susan R. Rippin